TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract that have spread (metastatic) or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine. This indication is approved based on medical studies that measured how many patients responded and how long they responded. Continued approval may depend on benefit demonstrated in additional medical studies. It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
Locally Advanced Bladder Cancer
Locally advanced, or muscle-invasive, bladder cancer refers to when the cancer cells have spread from where they started to nearby tissues, like muscles, or to lymph nodes. With locally advanced bladder cancer, this means that the cancer may have spread to organs or tissues close to the bladder, such as the prostate in men, or the uterus, cervix, or vagina in women.
Metastatic Bladder Cancer
Metastatic bladder cancer refers to when cancer cells have spread outside from the bladder and surrounding tissues to other parts of the body.
These are some things to consider when discussing your treatment plan for advanced bladder cancer with your healthcare provider. Sharing this information can help you and your healthcare team decide what your next treatment option could be.
Other Conditions You May Have
You’ll want to bring up any current conditions you have been diagnosed with. About 1 out of every 4 people (23.4%) with advanced bladder cancer also has diabetes. Other common conditions include kidney disease (16.5%), chronic obstructive pulmonary disease, or COPD (12.4%), heart disease (5.1%), and stroke (4.7%). Knowing about your overall health will help your healthcare provider develop the best treatment plan for you.
Treatments You’ve Tried
Your treatment considerations may change over time. It is important to talk to your healthcare provider about any new signs or symptoms you have experienced during your treatment journey for advanced bladder cancer. Discuss any treatments you may have tried in the past and any side effects you may have experienced.
Together with your healthcare provider, take control of your treatment plan with TRODELVY.
TRODELVY is a type of treatment called an antibody-drug conjugate (ADC). It is designed to carry anticancer medicine to cells that have the Trop-2 protein. Trop-2 is more often present on certain types of cancer cells, including advanced bladder cancer cells, compared to normal cells. See how TRODELVY is designed to work.
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract that have spread or cannot be removed by surgery. TRODELVY may be used if you have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine.*
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems. It is not known if TRODELVY is safe and effective in children.
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract that have spread (metastatic) or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine.
This indication is approved based on medical studies that measured how many patients responded and how long they responded. Continued approval may depend on benefit demonstrated in additional medical studies.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.
Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).
Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.
Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.
The most common side effects of TRODELVY include decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts, feeling tired or weak, hair loss, constipation, increased sugar levels in the blood, decreased protein levels (albumin) in the blood, decreased appetite, changes in kidney function test, increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems), and decreased levels of magnesium, potassium, and sodium in the blood.
These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click to see Important Facts about TRODELVY, including Important Warning.